<SEC-DOCUMENT>0001104659-20-066624.txt : 20200528
<SEC-HEADER>0001104659-20-066624.hdr.sgml : 20200528
<ACCEPTANCE-DATETIME>20200528065711
ACCESSION NUMBER:		0001104659-20-066624
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200527
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200528
DATE AS OF CHANGE:		20200528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		20916893

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			2161401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2021026d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): May 28, 2020 (May 27, 2020)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protalix BioTherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>001-33357</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><B>65-0643773</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>(Commission File Number)</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>2 Snunit Street</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>2161401</B></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>Science Park, POB 455</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>Carmiel, Israel</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>(Address of principal executive offices)</B></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; text-align: center"><B>(Zip Code)</B></TD></TR>
<TR>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code +972-4-988-9488</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communication pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 39%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Title of each class</TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Trading Symbol(s)</TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common stock, $0.001 par value</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">PLX</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">NYSE American</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: center; text-indent: 0.5in">Emerging growth
company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B>
Item 8.01</B></TD>
    <TD><B>Other Events</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May&nbsp;28, 2020, Protalix BioTherapeutics, Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), issued a press release, together with its development and commercialization partner, Chiesi
Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;), announcing the submission on May 27, 2020 of
a Biologics License Application (BLA) to the U.S.&nbsp;Food and Drug Administration (FDA) for pegunigalsidase alfa for the proposed
treatment of adult patients with Fabry disease via the FDA&rsquo;s Accelerated Approval pathway. Pegunigalsidase alfa is the Company&rsquo;s
purposefully-designed, long-acting recombinant, PEGylated, cross-linked &alpha;-galactosidase-A investigational product candidate.
A copy of the press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8<FONT STYLE="color: #333333">-</FONT>K
and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>
</B></FONT><B>Item 9.01</B></TD>
    <TD STYLE="padding-bottom: 10pt"><B>Financial Statements and Exhibits</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt"><B>(d)</B></TD>
    <TD STYLE="padding-bottom: 10pt"><B>Exhibits</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt"><A HREF="tm2021026d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="padding-bottom: 10pt"><A HREF="tm2021026d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press release dated May&nbsp;28, 2020.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR>
    <TD STYLE="text-align: justify">Date: May&nbsp;28, 2020</TD>
    <TD COLSPAN="4" STYLE="text-align: justify"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></TD></TR>
<TR>
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 6%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 29%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;/s/ Dror Bashan</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Name: </TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">Dror Bashan</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Title:</TD>
    <TD COLSPAN="2" STYLE="text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2021026d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle"><IMG SRC="logo1.gif" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: middle"><IMG SRC="logo2.gif" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Protalix BioTherapeutics and Chiesi Global
Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa
for the Treatment of Fabry Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CARMIEL, Israel, </B>May 28, 2020
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development,
production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<SUP>&reg;</SUP> plant
cell-based protein expression system, or the Company, together with its development and commercialization partner Chiesi Global
Rare Diseases, a unit of Chiesi, an international research-focused healthcare group, today announced the submission on May 27,
2020 of a Biologics License Application (BLA) to the U.S.&nbsp;Food and Drug Administration (FDA) for pegunigalsidase alfa for
the proposed treatment of adult patients with Fabry disease via the FDA&rsquo;s Accelerated Approval pathway. Pegunigalsidase
alfa, or PRX-102, was granted Fast Track designation by the FDA in January 2018. Pegunigalsidase alfa is the Company&rsquo;s purposefully-designed,
long-acting recombinant, PEGylated, cross-linked &alpha;-galactosidase-A investigational product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #242424">The BLA submission includes </FONT>a
comprehensive set of preclinical, clinical and manufacturing <FONT STYLE="color: #242424">data compiled from </FONT>the Company&rsquo;s
completed Phase&nbsp;I/II clinical trial of pegunigalsidase alfa<FONT STYLE="color: #242424">, including </FONT>the related extension
study succeeding the Phase&nbsp;I/II clinical trial<FONT STYLE="font-size: 10pt">,</FONT> <FONT STYLE="color: #242424">interim
clinical data from the Phase</FONT>&nbsp;III <FONT STYLE="color: #242424">BRIDGE switch-over study and safety data from the Company&rsquo;s
on-going clinical studies of PRX-102. Upon the BLA </FONT>approval, if approved, the Company will be eligible to receive a milestone
payment from Chiesi.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;We are grateful for the assistance
the FDA provided leading up to the submission of this BLA via the Accelerated Approval pathway, and we look forward, together with
Chiesi, to working with the FDA as we seek marketing approval for PRX<FONT STYLE="color: #242424">-</FONT>102,&rdquo; said Dror
Bashan, Protalix&rsquo;s President and Chief Executive Officer. &ldquo;Together with Chiesi, we thank the investigators and study
participants who have made reaching this milestone possible and have supported Protalix in our commitment to bringing this new
treatment option to the Fabry patient community.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The submission of this BLA to the FDA represents a significant
milestone for our Global Rare Diseases division that was established earlier this year to strengthen Chiesi&rsquo;s focus on making
a difference for patients living with rare diseases around the world,&rdquo; said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
 &ldquo;Our partnership and active collaboration with Protalix are a great example showing how we can leverage Chiesi&rsquo;s global
reach and decades of experience in drug development to support patients and their families living with Fabry disease and many other
devastating rare diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Fabry Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fabry disease is an X-linked inherited disease that results
from deficient activity of the lysosomal &alpha;-Galactosidase-A enzyme resulting in progressive accumulation of abnormal deposits
of a fatty substance called globotriaosylceramide (Gb<SUB>3</SUB>) in blood vessel walls throughout a person&rsquo;s body. Fabry
disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &alpha;-Galactosidase-A enzyme, which
is normally responsible for the breakdown of Gb<SUB>3</SUB>. The abnormal storage of Gb<SUB>3</SUB> increases with time and, accordingly,
Gb<SUB>3</SUB> accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb<SUB>3</SUB> deposition
range from episodes of pain and impaired peripheral sensation to end-organ failure &ndash; particularly of the kidneys, but also
of the heart and the cerebrovascular system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Pegunigalsidase Alfa</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pegunigalsidase alfa (PRX<FONT STYLE="color: #242424">-</FONT>102)
is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant &alpha;-Galactosidase-A
enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with
unique pharmacokinetic parameters. In clinical studies, PRX<FONT STYLE="color: #242424">-</FONT>102 has been observed to have a
circulatory half-life of approximately 80 hours. The Company designed PRX-102 to potentially address the continued unmet clinical
need in Fabry patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Chiesi Global Rare Diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chiesi Global Rare Diseases is a business unit of the Chiesi
Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The
Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global
network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments
available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Chiesi Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based in Parma, Italy, Chiesi Farmaceutici is an international
research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries.
Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease
areas. Its R&amp;D organization is headquartered in Parma (Italy), and is integrated with R&amp;D groups in France, the USA, the
UK, and Sweden to advance Chiesi's pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people. Chiesi
Group is a certified Benefit Corporation. For more information <FONT STYLE="color: Blue"><U>www.chiesi.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Protalix BioTherapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix is a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system,
ProCellEx<SUP>&reg;</SUP>. Protalix was the first company to gain U.S.&nbsp;Food and Drug Administration (FDA) approval of a protein
produced through plant cell-based in suspension expression system. Protalix&rsquo;s unique expression system represents a new method
for developing recombinant proteins in an industrial-scale manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix&rsquo;s first product manufactured by ProCellEx, taliglucerase
alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix
has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where
Protalix retains full rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protalix&rsquo;s development pipeline consists of proprietary
versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates:
pegunigalsidase alfa, a modified version of the recombinant human &alpha;-Galactosidase-A protein for the proposed treatment of
Fabry disease; OPRX<FONT STYLE="color: #242424">-</FONT>106, an orally-delivered anti-inflammatory treatment; alidornase alfa for
the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States
and outside the United States, for the development and commercialization of pegunigalsidase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;should&rdquo; and &ldquo;intend,&rdquo; and other words or phrases of similar
import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements
are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree
of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors
that might cause material differences include, among others: that the FDA might not grant marketing approval for PRX<FONT STYLE="color: #242424">-</FONT>102
in the currently anticipated timeline or at all and, if approved, whether PRX<FONT STYLE="color: #242424">-</FONT>102 will be commercially
successful; failure or delay in the commencement or completion of our preclinical and clinical trials which may be caused by several
factors, including: risks that the FDA will not accept an application for accelerated approval of PRX<FONT STYLE="color: #242424">-</FONT>102
with the data generated to date or will request additional data or other conditions of our submission of any application for accelerated
approval of PRX<FONT STYLE="color: #242424">-</FONT>102; slower than expected rates of patient recruitment; unforeseen safety issues;
determination of dosing issues; lack of effectiveness during clinical trials; inability to monitor patients adequately during or
after treatment; and inability or unwillingness of medical investigators and institutional review boards to follow our clinical
protocols; risks associated with the novel coronavirus disease (COVID<FONT STYLE="color: #242424">-</FONT>19) outbreak, which may
adversely impact our business, preclinical studies and clinical trials; the risk that the results of the clinical trials of our
product candidates will not support our claims of safety or efficacy, that our product candidates will not have the desired effects
or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain
and manage our relationship with Chiesi Farmaceutici and any other collaborator, distributor or partner; risks related to the amount
of our future revenues and expenditures; the risk that despite the FDA&rsquo;s grant of Fast Track designation for PRX-102, we
may not experience a faster development process, review or approval compared to applications considered for approval under conventional
FDA procedures; risks related to the FDA&rsquo;s ability to withdraw the Fast Track designation at any time; our dependence on
performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in
the approval or potential rejection of any applications we file with the FDA or other health regulatory authorities, and other
risks relating to the review process; the inherent risks and uncertainties in developing drug platforms and products of the type
we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential
product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and
other factors described in our filings with the U.S.&nbsp;Securities and Exchange Commission. The statements in this press release
are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737"><B>Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">Chuck Padala, Managing
Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">646-627-8390</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue"><FONT STYLE="color: Blue"><U>chuck@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">Brian Pinkston</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">LaVoieHealthScience</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #373737">857-588-3347</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue"><FONT STYLE="color: Blue"><U>bpinkston@lavoiehealthscience.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: #373737">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.gif
M1TE&.#EAJP T /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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;%S=6O&(&J2K>\IKW(.0]KWK-F][U+B0@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.gif
M1TE&.#EAMP ^ /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
M,\P  )G__YG_S)G_F9G_9IG_,YG_ )G,_YG,S)G,F9G,9IG,,YG, )F9_YF9
MS)F9F9F99IF9,YF9 )EF_YEFS)EFF9EF9IEF,YEF )DS_YDSS)DSF9DS9IDS
M,YDS )D _YD S)D F9D 9ID ,YD  &;__V;_S&;_F6;_9F;_,V;_ &;,_V;,
MS&;,F6;,9F;,,V;, &:9_V:9S&:9F6:99F:9,V:9 &9F_V9FS&9FF69F9F9F
M,V9F &8S_V8SS&8SF68S9F8S,V8S &8 _V8 S&8 F68 9F8 ,V8  #/__S/_
MS#/_F3/_9C/_,S/_ #/,_S/,S#/,F3/,9C/,,S/, #.9_S.9S#.9F3.99C.9
M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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'HNLG(   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
